Anti-cancer breakthrough! Lysovirus in conjunction with CAR-T efficacy 1 >2?

Recently, scientists at Hope City National Medical Center in the United States combined two immunotherapies, lysovirus and CAR-T cell therapy, to overcome the micro-environment effects of tumors, successfully targeting and eradicating solid tumors that would otherwise be difficult to treat with CAR-T therapy alone.
, the lysovirus was pushed to the forefront and re-entered the public eye.
reported that there are currently more than 100 clinical trials of the lysovirus under way around the world.
2020 domestic lysovirus development is also in full swing, involved in nearly 10 well-known team of experts, more than 40 enterprises.
varieties have the introduction of large-sized medicine blister-like oral tumor virus products, the introduction of biosoloma virus products C-REV and a number of domestic enterprises in the independent and joint research and development of related lysolycovirus products, and so on.
of lysovirus products, triggering a new wave of drug companies to catch lysovirus.
so the lysovirus will be a long-standing problem in the medical profession - cancer star? What challenges are facing the development of the lysovirus industry in China? At the end of the 19th century, a 42-year-old woman with leukemia suddenly recovered from a suspected flu infection; in 1912, Italian doctors reported that a terminal cervical cancer patient was in significant remission after being vaccinated against rabies. The above examples have made scientists aware that certain viruses can kill tumor cells.
In 1991, Harvard University's Martuza et al. published an article in Science that said that genetically modified herpes simplex virus HSV had a certain effect in the treatment of malignant glioma, the treatment of the lysolytic virus using HSV becoming increasingly concerned; Menottia and other researchers conducted a study to try to use modified HSVs for the treatment of lysovirus in HER-2-positive tumors..." The development of lysomavirus can be broadly divided into three stages: wild virus strain discovery and application phase (1904-1990), genetically modified virus strain development stage (1991-2010) and gene insertion and joint therapy efficiency phase (2010-present).
has experienced the use of non-human infection viruses, mild human response viruses and gene recombinant viruses targeting tumors, " Li said.
today, lysovirus can still arouse widespread concern and become an important immunotherapy involved in the treatment of tumors.
" has now developed to the third generation, including herpes virus, enterovirus, bovine pox virus, including more than a dozen viruses have been developed into lysovirus drugs and into clinical trials.
Li said that many domestic and foreign pharmaceutical companies are competing to carry out immunotherapy research on tumor tumors of lysovirus, and actively explore the potential of immunocommunication therapy for tumors of lysovirus.
" lysovirus identifies cancer characteristics through biosignals (biomarkers).
different tumors in different populations, their biological signals are very different.
types of cancer are also many, at present, the lysovirus can only treat some surface tumors or site-limiting tumors, the effects of other diseases are rarely reported."
Professor Li introduced that the lysovirus, is not a omnary "professional killer", but it can specifically identify cancer cells, high selectivity, the normal cytotoxicity of the human body is very low, "it is called 'professional killer of cancer cells' is not necessarily indispensable."
" lysovirus drug development recommendations in recent years, Cancer morbidity and mortality in China continue to rise, an average of more than 10,000 people are diagnosed every day, every minute more than 5 people died of cancer, the risk of cancer is increasing year by year.
With more and more families shrouded in the shadow of cancer, finding a safer and more effective cancer treatment in the absence of a relatively effective treatment is a patient's fervent hope and a driving force for scientists to develop day and night.
"In the next 5-10 years, more cancers may be cured by the lysovirus."
" for the development of lysovirus-type drugs, Professor Li gave his own advice.
first, innovative lysovirus research and development.
selection and modification of virus species and functional genes is the source innovation of lysovirus, but the commonly used virus species and gene recombination methods have been extensively developed and patented.
" innovative research and development, preempt the opportunity, for pharmaceutical companies is the current focus of lysovirus product research and development.
" second, industrialization development.
China's lysovirus preparation technology has been initially mature, but there is still a certain gap in large-scale industrialization, "to do patients can afford the drug, is the original intention of continuous innovation and research and development, in order to make innovative research and development continue."
" third, there are still no specific regulatory guidelines for the manufacture and manifestations of clinical use of lysovirus.
with the development of lysovirus-type drugs, it is found that these drugs have more unique consideration points in clinical trial design.
ICH and EMA, FDA do not have relevant technical guidelines.
" in August this year, CDE publicly solicited the Guidelines for the Design of Clinical Trials of Lysovirus-type Drugs (Draft for Comments), which will help guide the regulation of clinical trials of lysovirus-type drugs.
," he said.
For the future development of the lysovirus market, Professor Li believes that, based on the advantages of system and targeting, lysolytovirus will bring new breakthroughs in the types of cancer, such as solid tumors, multi-dimensional attack on diseases, joint treatment, will be worth exploring the direction.